UI Hospitals and Clinics
A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy, MCL-2001
Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL), which has been previously treated and the disease has returned. The purpose of the study is to assess the effects (both good and bad) of Ibrutinib in MCL and whether the MCL responds to treatment. The Study treatment is a maximum of 3 years, depending on how well the participant responds to treatment.
Mary Schall 319-356-3516
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.